{"doc_id": "PMC-1472690-12-Methods-04.txt", "sent_id": "", "tokens": ["Oligonucleotides", "(", "Oligos", ")", "and", "5'-32-P-Labeling"], "sentence": "Oligonucleotides ( Oligos ) and 5'-32-P-Labeling", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMC-1472690-12-Methods-04.txt", "sent_id": "S2", "tokens": ["The", "complementary", "double-stranded", "(", "ds", ")", "oligonucleotides", "(", "oligos", ")", "from", "the", "TNFalpha", ",", "IL-8", ",", "IFNgamma", "and", "IL-6", "promoters", "were", "synthesised", "from", "single", "stranded", "(", "ss", ")", "oligos", "(", "illustrated", "in", "Table", "1", ")", ",", "(", "TIB", "Molbiol", ",", "Berlin", ",", "Germany", ")", "and", "32P-labeled", "with", "5'gamma-P-ATP", "(", "3", ",", "000", "Ci", "/", "mmol", ",", "Amersham", ",", "Braunschweig", ",", "Germany", ")", "using", "the", "Ready-To-Go-Polynucleotide-Kinase", "Kit", "(", "PNK", "Kit", ",", "Pharmacia", "LKB", ",", "Freiburg", ",", "Germany", ")", "according", "to", "the", "manufacturer", "'s", "instructions", "."], "sentence": "The complementary double-stranded ( ds ) oligonucleotides ( oligos ) from the TNFalpha , IL-8 , IFNgamma and IL-6 promoters were synthesised from single stranded ( ss ) oligos ( illustrated in Table 1 ) , ( TIB Molbiol , Berlin , Germany ) and 32P-labeled with 5'gamma-P-ATP ( 3 , 000 Ci / mmol , Amersham , Braunschweig , Germany ) using the Ready-To-Go-Polynucleotide-Kinase Kit ( PNK Kit , Pharmacia LKB , Freiburg , Germany ) according to the manufacturer 's instructions .", "event_mentions": [], "entity_mentions": [{"id": "T1", "text": "TNFalpha", "entity_type": "Protein", "start": 12, "end": 12}, {"id": "T2", "text": "IL-8", "entity_type": "Protein", "start": 14, "end": 14}, {"id": "T3", "text": "IFNgamma", "entity_type": "Protein", "start": 16, "end": 16}, {"id": "T4", "text": "IL-6", "entity_type": "Protein", "start": 18, "end": 18}]}
{"doc_id": "PMC-1472690-12-Methods-04.txt", "sent_id": "", "tokens": ["To", "test", "the", "binding", "specificity", "of", "the", "oligos", ",", "mutated", "oligos", "were", "used", "as", "an", "additional", "control", "."], "sentence": "To test the binding specificity of the oligos , mutated oligos were used as an additional control .", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMC-1472690-12-Methods-04.txt", "sent_id": "S4", "tokens": ["Mutations", "in", "the", "P2", "site", "of", "the", "IFNgamma", "promoter", "[", "29", "]", "and", "in", "the", "kappa", "consensus", "sequence", "of", "the", "TNFalpha", "promoter", "[", "55", "]", "have", "been", "reported", "to", "interfere", "with", "sequences", ",", "which", "seem", "to", "be", "crucial", "for", "the", "binding", "of", "NFAT", "and", "NFkappaB", "proteins", ",", "respectively", "."], "sentence": "Mutations in the P2 site of the IFNgamma promoter [ 29 ] and in the kappa consensus sequence of the TNFalpha promoter [ 55 ] have been reported to interfere with sequences , which seem to be crucial for the binding of NFAT and NFkappaB proteins , respectively .", "event_mentions": [], "entity_mentions": [{"id": "T5", "text": "IFNgamma", "entity_type": "Protein", "start": 7, "end": 7}, {"id": "T6", "text": "TNFalpha", "entity_type": "Protein", "start": 20, "end": 20}, {"id": "T7", "text": "NFAT", "entity_type": "Protein", "start": 42, "end": 42}]}
{"doc_id": "PMC-1472690-12-Methods-04.txt", "sent_id": "", "tokens": ["Afterwards", ",", "the", "ds", "oligos", "were", "purified", "via", "gel", "filtration", "using", "Probe", "Quant", "G-50", "Micro", "Columns", "(", "Pharmacia", ")", "according", "to", "the", "manufacturer", "'s", "instructions", "."], "sentence": "Afterwards , the ds oligos were purified via gel filtration using Probe Quant G-50 Micro Columns ( Pharmacia ) according to the manufacturer 's instructions .", "event_mentions": [], "entity_mentions": []}
